Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Hudson |
RCV000209885 | SCV000265507 | uncertain significance | Severe myoclonic epilepsy in infancy | 2021-09-01 | criteria provided, single submitter | research | |
Gene |
RCV000494091 | SCV000582178 | uncertain significance | not provided | 2022-09-15 | criteria provided, single submitter | clinical testing | Observed in an individual with developmental delay or intellectual disability; however segregation and detailed clinical information was not provided (Hiatt et al., 2018); This substitution is predicted to be in the cytoplasmic loop between the third and fourth homologous domains; Missense variants in this gene are often considered pathogenic (HGMD); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; This variant is associated with the following publications: (PMID: 29655203, 29652076) |
Labcorp Genetics |
RCV000702992 | SCV000831870 | likely benign | Early infantile epileptic encephalopathy with suppression bursts | 2023-11-17 | criteria provided, single submitter | clinical testing | |
Prevention |
RCV004528267 | SCV004105789 | uncertain significance | SCN1A-related disorder | 2023-08-09 | criteria provided, single submitter | clinical testing | The SCN1A c.4547C>T variant is predicted to result in the amino acid substitution p.Ser1516Leu. This variant was reported in an individual with an unspecified epilepsy and/or neurodevelopmental disorder (Table S4, Lindy et al. 2018. PubMed ID: 29655203). This variant is reported in 0.013% of alleles in individuals of South Asian descent in gnomAD (http://gnomad.broadinstitute.org/variant/2-166852557-G-A). At this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence. |
Mayo Clinic Laboratories, |
RCV000494091 | SCV004224979 | uncertain significance | not provided | 2022-03-17 | criteria provided, single submitter | clinical testing | PP3 |